The impact of impurities in synthetic peptides on the outcome of T‐cell stimulation assays
Identifieur interne : 001391 ( Istex/Curation ); précédent : 001390; suivant : 001392The impact of impurities in synthetic peptides on the outcome of T‐cell stimulation assays
Auteurs : Janet W. De Beukelaar [Pays-Bas] ; Jan W. Gratama [Pays-Bas] ; Peter A. Sillevis Smitt [Pays-Bas] ; Georges M. Verjans [Pays-Bas] ; Jaco Kraan [Pays-Bas] ; Theo M. Luider [Pays-Bas] ; Peter C. Burgers [Pays-Bas]Source :
- Rapid Communications in Mass Spectrometry [ 0951-4198 ] ; 2007-04-15.
English descriptors
- Teeft :
- Amino, Amino acid, Amino acids, Assay, Assay outcome, Base peak, Base peak protonated peptide, Batch, Charge delocalization, Commun, Comparative analysis, Complete series, Copyright, Deletion, Deletion peptide, Deletion peptides, Different batches, Different purities, Erasmus university, Exact mass, Exact mass measurements, Exact mass measurements show, External calibration, Fragmentation conditions, Ftms, Ftms spectra, Impurity, Isotope peak, John wiley sons, Liquid chromatography, Mass spectra, Mass spectrom, Mass spectrometry, Mass spectrum, Negative control, Netherlands proteomics centre, Numerous differences, Partial ftms spectrum, Peptide, Peptide batches, Peptide impurity, Peptide pools, Peptide synthesis, Positive responses, Product ions, Protonated, Protonated peptide, Purity batch, Purity peptides, Rapid commun, Same manufacturer, Same peptide, Sequence gftmtnydeaamai, Spectrom, Strong calcium, Such experiments, Sulfated, Sulfated peptide, Sulfated peptides, Synthesis method, Synthetic peptide, Synthetic peptides, Target plate, Wide range.
Abstract
Protein‐spanning peptide pools have proven valuable as a screening tool for detecting T‐lymphocyte responses against a wide range of proteins. We have used this approach in our search for T cells reactive to the onconeural protein HuD. We found positive responses in only 3 of 127 individuals; however, these were highly unusual in that the same class I HLA alleles and peptides were involved. These T‐cell responses were not confirmed when peptides re‐synthesized by the same manufacturer with similar and with higher purity levels were used. Our observations indicated that these T‐cell responses were not directed against the designed HuD peptides. Here, we report on (i) comparisons of the peptide batches analyzed by matrix‐assisted laser desorption/ionization Fourier transform mass spectrometry (MALDI‐FTMS) that did –and did not – elicit T‐cell responses and (ii) a detailed analysis of the various by‐products of peptides, irrespective of T‐cell assay outcome. We found numerous differences between the peptide batches, such as omissions of amino acids in the primary structure of the peptides. Furthermore, some batches revealed strong interactions with calcium ions or contained sulfated peptides. Our data reveal that different batches from the same peptide may contain artefacts that influence the outcome of HLA‐restricted T‐cell response assays. Copyright © 2007 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/rcm.2958
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001391
Links to Exploration step
ISTEX:7818C549B65474CE51DF32F3A47DA61BFF72AD77Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The impact of impurities in synthetic peptides on the outcome of T‐cell stimulation assays</title><author><name sortKey="De Beukelaar, Janet W" sort="De Beukelaar, Janet W" uniqKey="De Beukelaar J" first="Janet W." last="De Beukelaar">Janet W. De Beukelaar</name><affiliation wicri:level="1"><mods:affiliation>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Gratama, Jan W" sort="Gratama, Jan W" uniqKey="Gratama J" first="Jan W." last="Gratama">Jan W. Gratama</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Smitt, Peter A Sillevis" sort="Smitt, Peter A Sillevis" uniqKey="Smitt P" first="Peter A. Sillevis" last="Smitt">Peter A. Sillevis Smitt</name><affiliation wicri:level="1"><mods:affiliation>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Verjans, Georges M" sort="Verjans, Georges M" uniqKey="Verjans G" first="Georges M." last="Verjans">Georges M. Verjans</name><affiliation wicri:level="1"><mods:affiliation>Department of Virology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Virology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Kraan, Jaco" sort="Kraan, Jaco" uniqKey="Kraan J" first="Jaco" last="Kraan">Jaco Kraan</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Luider, Theo M" sort="Luider, Theo M" uniqKey="Luider T" first="Theo M." last="Luider">Theo M. Luider</name><affiliation wicri:level="1"><mods:affiliation>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Burgers, Peter C" sort="Burgers, Peter C" uniqKey="Burgers P" first="Peter C." last="Burgers">Peter C. Burgers</name><affiliation wicri:level="1"><mods:affiliation>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: p.burgers@erasmusmc.nl</mods:affiliation><country wicri:rule="url">Pays-Bas</country></affiliation><affiliation wicri:level="1"><mods:affiliation>Correspondence address: Laboratory of Neuro‐Oncology, Department of Neurology Erasmus University Medical Center, Dr. Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands.</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Correspondence address: Laboratory of Neuro‐Oncology, Department of Neurology Erasmus University Medical Center, Dr. Molewaterplein 50, 3015 GE, Rotterdam</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7818C549B65474CE51DF32F3A47DA61BFF72AD77</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/rcm.2958</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-7R5S48B6-D/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001391</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001391</idno><idno type="wicri:Area/Istex/Curation">001391</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The impact of impurities in synthetic peptides on the outcome of T‐cell stimulation assays</title><author><name sortKey="De Beukelaar, Janet W" sort="De Beukelaar, Janet W" uniqKey="De Beukelaar J" first="Janet W." last="De Beukelaar">Janet W. De Beukelaar</name><affiliation wicri:level="1"><mods:affiliation>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Gratama, Jan W" sort="Gratama, Jan W" uniqKey="Gratama J" first="Jan W." last="Gratama">Jan W. Gratama</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Smitt, Peter A Sillevis" sort="Smitt, Peter A Sillevis" uniqKey="Smitt P" first="Peter A. Sillevis" last="Smitt">Peter A. Sillevis Smitt</name><affiliation wicri:level="1"><mods:affiliation>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Verjans, Georges M" sort="Verjans, Georges M" uniqKey="Verjans G" first="Georges M." last="Verjans">Georges M. Verjans</name><affiliation wicri:level="1"><mods:affiliation>Department of Virology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Virology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Kraan, Jaco" sort="Kraan, Jaco" uniqKey="Kraan J" first="Jaco" last="Kraan">Jaco Kraan</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Luider, Theo M" sort="Luider, Theo M" uniqKey="Luider T" first="Theo M." last="Luider">Theo M. Luider</name><affiliation wicri:level="1"><mods:affiliation>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation></author><author><name sortKey="Burgers, Peter C" sort="Burgers, Peter C" uniqKey="Burgers P" first="Peter C." last="Burgers">Peter C. Burgers</name><affiliation wicri:level="1"><mods:affiliation>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Laboratory of Neuro‐Oncology, Department of Neurology, Erasmus University Medical Center, Rotterdam</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: p.burgers@erasmusmc.nl</mods:affiliation><country wicri:rule="url">Pays-Bas</country></affiliation><affiliation wicri:level="1"><mods:affiliation>Correspondence address: Laboratory of Neuro‐Oncology, Department of Neurology Erasmus University Medical Center, Dr. Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands.</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Correspondence address: Laboratory of Neuro‐Oncology, Department of Neurology Erasmus University Medical Center, Dr. Molewaterplein 50, 3015 GE, Rotterdam</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Rapid Communications in Mass Spectrometry</title><title level="j" type="alt">RAPID COMMUNICATIONS IN MASS SPECTROMETRY</title><idno type="ISSN">0951-4198</idno><idno type="eISSN">1097-0231</idno><imprint><biblScope unit="vol">21</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1282">1282</biblScope><biblScope unit="page" to="1288">1288</biblScope><biblScope unit="page-count">7</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2007-04-15">2007-04-15</date></imprint><idno type="ISSN">0951-4198</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0951-4198</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Amino</term><term>Amino acid</term><term>Amino acids</term><term>Assay</term><term>Assay outcome</term><term>Base peak</term><term>Base peak protonated peptide</term><term>Batch</term><term>Charge delocalization</term><term>Commun</term><term>Comparative analysis</term><term>Complete series</term><term>Copyright</term><term>Deletion</term><term>Deletion peptide</term><term>Deletion peptides</term><term>Different batches</term><term>Different purities</term><term>Erasmus university</term><term>Exact mass</term><term>Exact mass measurements</term><term>Exact mass measurements show</term><term>External calibration</term><term>Fragmentation conditions</term><term>Ftms</term><term>Ftms spectra</term><term>Impurity</term><term>Isotope peak</term><term>John wiley sons</term><term>Liquid chromatography</term><term>Mass spectra</term><term>Mass spectrom</term><term>Mass spectrometry</term><term>Mass spectrum</term><term>Negative control</term><term>Netherlands proteomics centre</term><term>Numerous differences</term><term>Partial ftms spectrum</term><term>Peptide</term><term>Peptide batches</term><term>Peptide impurity</term><term>Peptide pools</term><term>Peptide synthesis</term><term>Positive responses</term><term>Product ions</term><term>Protonated</term><term>Protonated peptide</term><term>Purity batch</term><term>Purity peptides</term><term>Rapid commun</term><term>Same manufacturer</term><term>Same peptide</term><term>Sequence gftmtnydeaamai</term><term>Spectrom</term><term>Strong calcium</term><term>Such experiments</term><term>Sulfated</term><term>Sulfated peptide</term><term>Sulfated peptides</term><term>Synthesis method</term><term>Synthetic peptide</term><term>Synthetic peptides</term><term>Target plate</term><term>Wide range</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Protein‐spanning peptide pools have proven valuable as a screening tool for detecting T‐lymphocyte responses against a wide range of proteins. We have used this approach in our search for T cells reactive to the onconeural protein HuD. We found positive responses in only 3 of 127 individuals; however, these were highly unusual in that the same class I HLA alleles and peptides were involved. These T‐cell responses were not confirmed when peptides re‐synthesized by the same manufacturer with similar and with higher purity levels were used. Our observations indicated that these T‐cell responses were not directed against the designed HuD peptides. Here, we report on (i) comparisons of the peptide batches analyzed by matrix‐assisted laser desorption/ionization Fourier transform mass spectrometry (MALDI‐FTMS) that did –and did not – elicit T‐cell responses and (ii) a detailed analysis of the various by‐products of peptides, irrespective of T‐cell assay outcome. We found numerous differences between the peptide batches, such as omissions of amino acids in the primary structure of the peptides. Furthermore, some batches revealed strong interactions with calcium ions or contained sulfated peptides. Our data reveal that different batches from the same peptide may contain artefacts that influence the outcome of HLA‐restricted T‐cell response assays. Copyright © 2007 John Wiley & Sons, Ltd.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001391 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001391 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:7818C549B65474CE51DF32F3A47DA61BFF72AD77
|texte= The impact of impurities in synthetic peptides on the outcome of T‐cell stimulation assays
}}
| This area was generated with Dilib version V0.6.33. |  |